Exenatide Once-weekly as a Treatment for Multiple System Atrophy
NCT04431713 on ClinicalTrials.gov · last registry update 2025-06-27
A small phase 2 — 50 participants, against a typical 110. The sponsor logged completion for 22 March 2024. Primary outcome, as filed: Change in UMSARS Score (Parts I+II) From Baseline.
- Status
- COMPLETED
- Phase
- P2
- Drug
- exenatideBydureon, Byetta
- Sponsor
- University College, London
- Sponsor type
- Other
- Enrollment
- 50
- Started
- 2020-09-16
- Primary completion
- 2024-03-22 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in UMSARS Score (Parts I+II) From Baseline
Conditions studied
Multiple System Atrophy
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.